Replimune Group, Inc.
Status: Publicly traded
Direct answer
Replimune Group, Inc. is publicly traded on NASDAQ under the ticker REPL.
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes...
Can you invest in Replimune Group, Inc.?
Yes. Replimune Group, Inc. trades publicly on NASDAQ as REPL.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Replimune Group, Inc.
Detailed equity research is provided by MarketSnap.